Navigation Links
Protein, Total, Body Fluid

ProductsProtein, Total, Body Fluid
Company ARUP Laboratories
Item Protein, Total, Body Fluid
Features 
Description ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' clients include more than half of the nation's university teaching hospitals and children's hospitals, major commercial laboratories, military and government facilities, and major clinics.
Info ARUP Laboratories
Customer Service: (800) 522-2787
Web site: http://www.aruplab.com

Related medicine products :

1. Array® 360 Protein, Serology and Drug System
2. Array® 360 CEAL Protein, Serology and Drug System
3. Bence Jones Protein, Qualitative Free Kappa & Lambda Light Chains, Urine
4. Bence Jones Protein, Quantitative Free Kappa Light Chains, Urine
5. Bence Jones Protein, Quantitative Free Lambda Light Chains, Urine
6. Bence Jones Protein, Quantitative Free Kappa & Lambda Light Chains, Urine
7. Bence Jones Protein, Quantitative Kappa, Urine
8. Bence Jones Protein, Quantitative Lambda, Urine
9. C-Reactive Protein, High Sensitivity
10. C-Reactive Protein, Neonatal
11. Electrophoresis, Protein, CSF
Other Medicine News:Health News:Baicalin might be a promising therapeutic tool for severe acute pancreatitis 2Health News:Ocular Pharma Company Charlesson Announces $2.35MM in New Funding 2Health News:Ocular Pharma Company Charlesson Announces $2.35MM in New Funding 3Health News:Ocular Pharma Company Charlesson Announces $2.35MM in New Funding 4Health News:Ocular Pharma Company Charlesson Announces $2.35MM in New Funding 5Health News:BIDMC Dyslexia Research Lab celebrates 25th anniversary 2Health News:Release 1.3 of SLIM Search Now Available 2Health News:New Cleveland Clinic Press Healthy Cookbook Helps Diabetic Kids 2Health News:ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan 2Health News:ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan 3Health News:ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan 4Health News:ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan 5Health News:ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan 6Health News:ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan 7
Breaking Medicine Technology:Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies 2Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies 3Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies 4Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies 5Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies 6Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies 7GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 2GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 3GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 4GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 5GSK Study Showed Targeted Therapy Combination Achieved 14 Month Overall Survival in Patients with Advanced Breast Cancer 6Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 2Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 3Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customer's Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders 4IMAGINE Software Unveils Advanced IMAGINEradiology 28TM 29 Features 47841 1IMAGINE Software Unveils Advanced IMAGINEradiology 28TM 29 Features 47841 2Americas Future Now Straw Poll 3A Progressives See Health Care Reform With Public Option As Top Priority 47838 1Americas Future Now Straw Poll 3A Progressives See Health Care Reform With Public Option As Top Priority 47838 2Medical Insurance Automotive and Safety Groups Call on Congress to Make This the 22Last Deadly Summer for Teens 22 by Swiftly Passing Federal Teen 47835 1Medical Insurance Automotive and Safety Groups Call on Congress to Make This the 22Last Deadly Summer for Teens 22 by Swiftly Passing Federal Teen 47835 2Medical Insurance Automotive and Safety Groups Call on Congress to Make This the 22Last Deadly Summer for Teens 22 by Swiftly Passing Federal Teen 47835 3